16381-6 |
Androstenedione^5th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --5th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16381-6 |
|
|
|
|
Observation |
|
|
|
0 |
Androst sp5 p chal SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp5; sp5 p chal; Spec; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
16382-4 |
Androstenedione^6th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16382-4 |
|
|
|
|
Observation |
|
|
|
0 |
Androst sp6 p chal SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp6; sp6 p chal; Spec; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
16383-2 |
Androstenedione^7th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16383-2 |
|
|
|
|
Observation |
|
|
|
0 |
Androst sp7 p chal SerPl-mCnc |
|
|
|
Y |
|
^7th spec pst XXX chal; After; CHEMISTRY.CHALLENGE TESTING; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp7; sp7 p chal; Spec; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
16384-0 |
Androstenedione^8th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --8th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16384-0 |
|
|
|
|
Observation |
|
|
|
0 |
Androst sp8 p chal SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp8; sp8 p chal; Spec; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
16385-7 |
Androstenedione^9th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16385-7 |
|
|
|
|
Observation |
|
|
|
0 |
Androst sp9 p chal SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp9; sp9 p chal; Spec; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
16386-5 |
Rifabutin |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
DEPRECATED |
Deprecated Rifabutin [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
16386-5 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Deprecated Rifabutin Islt MIC |
|
|
|
|
|
Ansamycin; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Mycobutin; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16387-3 |
Rifabutin+Ethambutol |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Rifabutin+Ethambutol [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
16387-3 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Rifabutin+Ethambutol Islt MIC |
|
|
|
|
|
Ansamycin; ANTIBIOTIC SUSCEPTIBILITIES; AST; Etambol; Ethamb; ID; Inagen; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Myambutol; Mycobutin; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
16388-1 |
Anticonvulsants |
Prid |
Urine |
Pt |
Nom |
|
|
ACTIVE |
Anticonvulsants [Identifier] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16388-1 |
|
|
|
|
Both |
|
|
|
0 |
Anticonvulsants Ur |
|
|
|
|
|
Anticonvuls; Anticonvulsant; Antiepileptic; Antiseizure; DRUG/TOXICOLOGY; Drugs; Identity or presence; Nominal; Point in time; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
16389-9 |
Antidepressants |
Prid |
Ser/Plas |
Pt |
Nom |
|
|
ACTIVE |
Antidepressants [Identifier] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16389-9 |
|
|
|
|
Both |
|
|
|
0 |
Antidepressants SerPl |
|
|
|
|
|
Addiction; Antidepres; Antidepressant; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Identity or presence; Illicit; Nominal; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
1639-4 |
Testosterone^pre 5000 U HCG IM |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Testosterone [Mass/volume] in Serum or Plasma --pre 5000 U HCG IM |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
1639-4 |
|
|
|
|
Observation |
|
|
|
0 |
Testost pre 5000 U CG IM SerPl-mCnc |
|
|
|
Y |
|
Before; CHEMISTRY.CHALLENGE TESTING; Chorionic gonadotropin stimulation test; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; pre 5000 U CG IM; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Testo; Testos; Testost |
2.34 |
1 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
16390-7 |
Antidiuretics |
Prid |
Urine |
Pt |
Nom |
|
|
ACTIVE |
Antidiuretics [Identifier] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16390-7 |
|
|
|
|
Both |
|
|
|
0 |
Antidiuretics Ur |
|
|
|
|
|
Antidiuretic; DRUG/TOXICOLOGY; Drugs; Identity or presence; Nominal; Point in time; Random; UA; UR; Urn |
2.19 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
16391-5 |
Antimony |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Antimony [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16391-5 |
|
|
|
|
Both |
|
|
|
0 |
Antimony Ur Ql |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; SB; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16392-3 |
Nuclear Ab |
PrThr |
Ser |
Pt |
Ord |
Rodent substrate |
|
ACTIVE |
Nuclear Ab [Presence] in Serum by Rodent substrate |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
16392-3 |
|
Rodent substrate |
|
|
Both |
|
|
|
0 |
ANA Ser Ql Rodent subst |
|
|
|
|
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; NA; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16393-1 |
Nuclear Ab |
ACnc |
Ser |
Pt |
Qn |
Rodent substrate |
|
ACTIVE |
Nuclear Ab [Units/volume] in Serum by Rodent substrate |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
16393-1 |
|
Rodent substrate |
|
|
Both |
|
|
|
0 |
ANA Ser Rodent subst-aCnc |
|
|
|
Y |
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Arbitrary concentration; Autoantibodies; Autoantibody; NA; Nuc; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Serum; SR |
2.69 |
1.0l |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
16394-9 |
Nuclear Ab |
PrThr |
Body fld |
Pt |
Ord |
IF |
|
ACTIVE |
Nuclear Ab [Presence] in Body fluid by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
16394-9 |
|
IF |
|
|
Both |
|
|
|
0 |
ANA Fld Ql IF |
|
|
|
|
|
ABS; Aby; ACIF; ANA; ANF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Antinuclear antibody; Autoantibodies; Autoantibody; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; FA; FANA; Fl; Fld; FLU; Fluid; Fluorescent antibody; Fluoresent; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; NA; Nuc; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Time Resolved Fluorescence; TRF |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16395-6 |
Antipsychotics |
Prid |
Urine |
Pt |
Nom |
|
|
ACTIVE |
Antipsychotics [Identifier] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16395-6 |
|
|
|
|
Both |
|
|
|
0 |
Antipsychotics Ur |
|
|
|
|
|
Antipsychotic; DRUG/TOXICOLOGY; Drugs; Identity or presence; neuroleptics; Nominal; Point in time; Random; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
164-4 |
Cephapirin |
Susc |
Isolate |
Pt |
Qn |
MLC |
|
ACTIVE |
Cephapirin [Susceptibility] by Minimum lethal concentration (MLC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
164-4 |
|
MLC |
|
|
Observation |
|
|
|
0 |
Cephapirin Islt MLC |
|
|
|
Y |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Cefadyl; ID; Infectious Disease; InfectiousDisease; Islt; Isol; MBC; Minimum bactericidal concentration; Minimum lethal concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
1640-2 |
Thyrotropin^30M post dose TRH IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Thyrotropin [Mass/volume] in Serum or Plasma --30 minutes post dose TRH IV |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
1640-2 |
|
|
|
|
Observation |
|
|
|
0 |
TSH 30M p TRH IV SerPl-mCnc |
|
|
|
Y |
|
30M p TRH; 30M p TRH IV; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Level; Mass concentration; p dose; p TRH; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Thyroid stimulating hormone; Thyrotropic hormone; TSH |
2.73 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16400-4 |
Observation |
Aper |
Semin plas |
Pt |
Nom |
|
|
ACTIVE |
Appearance of Seminal plasma |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
16400-4 |
|
|
|
|
Observation |
|
|
|
0 |
Appearance Semin plas |
|
|
|
|
|
Appearance; Nominal; Pl; Plasma; Plsm; Point in time; Random; Seminal plasma; SPEC |
2.79 |
1.0l |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by coll w SCT: component that the description is property like as in Color, Appearance, Osmolality have changed to Component: Observation, and Property: Color, or Appearance, or Osmolality, so forth�; |
0 |
16401-2 |
Arginine |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Arginine [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16401-2 |
|
|
|
|
Observation |
|
|
|
0 |
Arginine Ur Ql |
|
|
|
|
|
Arg; Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16402-0 |
Aromatic solvents |
Prid |
Bld |
Pt |
Nom |
|
|
ACTIVE |
Aromatic solvents [Identifier] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16402-0 |
|
|
|
|
Both |
|
|
|
0 |
Arom Solvents Bld |
|
|
|
|
|
Arom Solvents; Blood; DRUG/TOXICOLOGY; Drugs; Identity or presence; Nominal; Point in time; Random; WB; Whole blood |
2.07 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
16403-8 |
Arsenic |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Arsenic [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16403-8 |
|
|
|
|
Both |
|
|
|
0 |
Arsenic SerPl Ql |
|
|
|
|
|
AS; DRUG/TOXICOLOGY; Drugs; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16404-6 |
Arsenic |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Arsenic [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16404-6 |
|
|
|
|
Both |
|
|
|
0 |
Arsenic Ur Ql |
|
|
|
|
|
AS; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16405-3 |
Arylamidase |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Arylamidase [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16405-3 |
|
|
|
|
Both |
|
|
|
0 |
Arylamidase Ur Ql |
|
|
|
|
|
Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16406-1 |
Arylamidase |
CCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Arylamidase [Enzymatic activity/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
arb U/L |
|
|
|
|
|
|
CHEM |
|
16406-1 |
|
|
|
|
Both |
|
|
|
0 |
Arylamidase Ur-cCnc |
|
|
|
Y |
|
Catalytic Concentration; Chemistry; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.68 |
1.0l |
|
|
|
|
|
|
|
U/L |
|
|
|
0 |